Literature DB >> 22776041

Ions, equations and electrons: the evolving role of computer simulations in cardiac electrophysiology safety evaluations.

Gary Gintant1.   

Abstract

Reliable preclinical cardiac safety evaluations of drug candidates are essential for selecting the best therapeutic agents. Advanced automated patch clamp technologies now allow for characterizing drug effects on multiple cardiac currents, enabling subsequent simulations of integrated electrophysiological responses on cellular, tissue and organ levels. In this issue, Mirams et al. summarize the strengths and limitations of models and simulations predicting drug-induced electrophysiological responses, emphasizing delayed repolarization and Torsades de Pointes pro-arrhythmia. The utility of computational approaches is contingent upon realistic models of ventricular electrophysiology, robust characterization of drug-channel interactions and an understanding of channel-myocyte interactions and pro-arrhythmic mechanisms. Simulations evaluating effects on repolarization (hazard identification) should aid in selecting safer drug candidates early in drug discovery, while simulations evaluating risk of Torsades de Pointes (incorporating known risk factors) should quantify pro-arrhythmic risk and reduce the need for costly clinical QT studies later in development. The wider adoption of realistic models and simulation studies will depend on simulation performance compared with 'gold standard' clinical findings.
© 2012 Abbott Laboratories. British Journal of Pharmacology © 2012 The British Pharmacological Society.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22776041      PMCID: PMC3492976          DOI: 10.1111/j.1476-5381.2012.02096.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  10 in total

Review 1.  An evaluation of hERG current assay performance: Translating preclinical safety studies to clinical QT prolongation.

Authors:  Gary Gintant
Journal:  Pharmacol Ther       Date:  2010-08-31       Impact factor: 12.310

2.  International Conference on Harmonisation; guidance on S7B Nonclinical Evaluation of the Potential for Delayed Ventricular Repolarization (QT Interval Prolongation) by Human Pharmaceuticals; availability. Notice.

Authors: 
Journal:  Fed Regist       Date:  2005-10-20

Review 3.  The thorough QT/QTc study 4 years after the implementation of the ICH E14 guidance.

Authors:  Borje Darpo
Journal:  Br J Pharmacol       Date:  2009-11-18       Impact factor: 8.739

4.  Quantitative comparison of cardiac ventricular myocyte electrophysiology and response to drugs in human and nonhuman species.

Authors:  Thomas O'Hara; Yoram Rudy
Journal:  Am J Physiol Heart Circ Physiol       Date:  2011-12-09       Impact factor: 4.733

5.  Robust anti-arrhythmic efficacy of verapamil and flunarizine against dofetilide-induced TdP arrhythmias is based upon a shared and a different mode of action.

Authors:  A Oros; M J Houtman; P Neco; A M Gomez; S Rajamani; P Oosterhoff; N J Attevelt; J D Beekman; M A G van der Heyden; L Ver Donck; L Belardinelli; S Richard; G Antoons; M A Vos
Journal:  Br J Pharmacol       Date:  2010-09       Impact factor: 8.739

Review 6.  The impact of drug-induced QT interval prolongation on drug discovery and development.

Authors:  Bernard Fermini; Anthony A Fossa
Journal:  Nat Rev Drug Discov       Date:  2003-06       Impact factor: 84.694

7.  Combined potassium and calcium channel blocking activities as a basis for antiarrhythmic efficacy with low proarrhythmic risk: experimental profile of BRL-32872.

Authors:  A Bril; B Gout; M Bonhomme; L Landais; J F Faivre; P Linee; R H Poyser; R R Ruffolo
Journal:  J Pharmacol Exp Ther       Date:  1996-02       Impact factor: 4.030

Review 8.  Sensitive and reliable proarrhythmia in vivo animal models for predicting drug-induced torsades de pointes in patients with remodelled hearts.

Authors:  A Sugiyama
Journal:  Br J Pharmacol       Date:  2008-06-16       Impact factor: 8.739

9.  Simulation of multiple ion channel block provides improved early prediction of compounds' clinical torsadogenic risk.

Authors:  Gary R Mirams; Yi Cui; Anna Sher; Martin Fink; Jonathan Cooper; Bronagh M Heath; Nick C McMahon; David J Gavaghan; Denis Noble
Journal:  Cardiovasc Res       Date:  2011-02-07       Impact factor: 10.787

Review 10.  Application of cardiac electrophysiology simulations to pro-arrhythmic safety testing.

Authors:  Gary R Mirams; Mark R Davies; Yi Cui; Peter Kohl; Denis Noble
Journal:  Br J Pharmacol       Date:  2012-11       Impact factor: 8.739

  10 in total
  3 in total

1.  A web portal for in-silico action potential predictions.

Authors:  Geoff Williams; Gary R Mirams
Journal:  J Pharmacol Toxicol Methods       Date:  2015-05-09       Impact factor: 1.950

Review 2.  The virtual heart as a platform for screening drug cardiotoxicity.

Authors:  Yongfeng Yuan; Xiangyun Bai; Cunjin Luo; Kuanquan Wang; Henggui Zhang
Journal:  Br J Pharmacol       Date:  2015-01-13       Impact factor: 8.739

3.  Prediction of Thorough QT study results using action potential simulations based on ion channel screens.

Authors:  Gary R Mirams; Mark R Davies; Stephen J Brough; Matthew H Bridgland-Taylor; Yi Cui; David J Gavaghan; Najah Abi-Gerges
Journal:  J Pharmacol Toxicol Methods       Date:  2014-07-31       Impact factor: 1.950

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.